To include your compound in the COVID-19 Resource Center, submit it here.

Combined inhibition of G12C-mutant KRAS, mTOR and IGF1R for NSCLC

DISEASE CATEGORY: Cancer

INDICATION: Non-small cell lung cancer (NSCLC)

Triple therapy with KRAS-G12C, mTOR and IGF1R inhibitors could treat KRAS G12C-mutant NSCLC. Whole genome screening of an shRNA library for targets whose

Read the full 304 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE